05:16 PM EST, 11/21/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) late Thursday said US regulators have approved its exenatide formulation as an adjunct treatment to help control glucose levels in the bloodstream of adults with type 2 diabetes mellitus.

The company plans to market pen injectors filled with the synthetic generic peptide in either 1.2-mililiter or 2.4-mililiter quantities.

The company also said it has resubmitted the new drug application for its dihydroergotamine injections for the treatment of migraine headaches to the US Food and Drug Administration.

Amneal shares recently were climbing 1% higher during after hours.